Bio-Rad Laboratories (US) introduces trilevel immunology control:
This article was originally published in Clinica
Bio-Rad Laboratories (US) has launched a new liquid, trilevel immunology control, designed to meet regulatory requirements for three distinct levels of control in specific immunological assays. Liquichek Immunology Controls shows level 1 as abnormally low, 2 as normal, and 3 as abnormally high, and can be used with all major nephelometers and other popular analysers and kits.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.